JP2005508983A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508983A5
JP2005508983A5 JP2003541843A JP2003541843A JP2005508983A5 JP 2005508983 A5 JP2005508983 A5 JP 2005508983A5 JP 2003541843 A JP2003541843 A JP 2003541843A JP 2003541843 A JP2003541843 A JP 2003541843A JP 2005508983 A5 JP2005508983 A5 JP 2005508983A5
Authority
JP
Japan
Prior art keywords
methyl
drug
dione
rheumatic
dmard
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003541843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508983A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/012415 external-priority patent/WO2003039552A1/en
Publication of JP2005508983A publication Critical patent/JP2005508983A/ja
Publication of JP2005508983A5 publication Critical patent/JP2005508983A5/ja
Pending legal-status Critical Current

Links

JP2003541843A 2001-11-09 2002-11-07 Ｐｄｅ４又はｐｄｅ３／４阻害剤及び抗リウマチ薬の複合薬 Pending JP2005508983A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01000607 2001-11-09
PCT/EP2002/012415 WO2003039552A1 (en) 2001-11-09 2002-11-07 Combination of pde4 or pde3/4 inhibitor and an anti-rheumatic drug

Publications (2)

Publication Number Publication Date
JP2005508983A JP2005508983A (ja) 2005-04-07
JP2005508983A5 true JP2005508983A5 (enExample) 2006-01-05

Family

ID=8176085

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003541843A Pending JP2005508983A (ja) 2001-11-09 2002-11-07 Ｐｄｅ４又はｐｄｅ３／４阻害剤及び抗リウマチ薬の複合薬

Country Status (6)

Country Link
US (2) US20030092706A1 (enExample)
EP (1) EP1448202A1 (enExample)
JP (1) JP2005508983A (enExample)
AU (1) AU2002300754B2 (enExample)
CA (1) CA2399840C (enExample)
WO (1) WO2003039552A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TR201815573T4 (tr) * 2002-05-28 2018-11-21 Astrazeneca Ab Topikal olarak uygulanabilir farmasötik preparasyon.
US6727272B1 (en) * 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
UA82323C2 (uk) * 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
DK1606261T3 (da) 2003-03-10 2010-01-18 Nycomed Gmbh Hidtil ukendt fremgangsmåde til fremstilling af roflumilast
US20070254928A1 (en) * 2004-05-10 2007-11-01 Altana Pharma Ag Use of Roflumilast for the Prophylaxis or Treatment of Emphysema
WO2006049215A1 (ja) * 2004-11-02 2006-05-11 Dainippon Sumitomo Pharma Co., Ltd. 自己免疫疾患を治療するための併用薬
WO2006099256A2 (en) * 2005-03-11 2006-09-21 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
AU2006224619B2 (en) * 2005-03-16 2012-06-07 Takeda Gmbh Taste masked dosage form containing roflumilast
KR100838702B1 (ko) * 2007-02-08 2008-06-16 한국화학연구원 1-[1-(3,4-디알콕시아릴)-피리딜메틸]-1ｈ-피라졸 화합물의제조방법
US20100203146A1 (en) * 2009-02-09 2010-08-12 Callisto Pharmaceuticals, Inc. Intermittent dosing strategy for treating rheumatoid arthritis
US20150098993A1 (en) * 2011-07-28 2015-04-09 Shireen Vali Compositions, process of preparation of said compositions and method of treating inflammatory diseases
AP2015008663A0 (en) 2013-02-19 2015-08-31 Pfizer Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
SG11201700243YA (en) 2014-08-06 2017-02-27 Pfizer Imidazopyridazine compounds
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1161239B1 (en) * 1999-03-10 2004-10-20 ALTANA Pharma AG 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis

Similar Documents

Publication Publication Date Title
CA2399840A1 (en) Use of roflumilast or pumafentrine in combination with methotrexate for the treatment of arthritic diseases
ES2991544T3 (es) Ketamina para el tratamiento de síntomas relacionados con la menstruación
ES2388425T5 (es) Composición farmacéutica no acuosa para uso dérmico para tratar la psoriasis que comprende una vitamina D, un corticoesteroide y un componente disolvente
ES2363334T3 (es) Combinaciones para el tratamiento de desórdenes inmuno-inflamatorios.
US10456390B2 (en) Combinations comprising MABA compounds and corticosteroids
EP3923920A1 (en) Ketamine for the treatment of postpartum symptoms and disorders
US20160015704A1 (en) Combinations comprising maba compounds and corticosteroids
Elad et al. Budesonide: a novel treatment for oral chronic graft versus host disease
US20090131382A1 (en) Treatment of rheumatoid arthritis using imatinib
JP6502876B2 (ja) 筋ジストロフィーの治療に用いられるジエチル−［６−（４−ヒドロキシカルバモイル−フェニル−カルバモイルオキシ−メチル）−ナフタレン−２−イル−メチル］−アンモニウムクロリド
KR20240128095A (ko) 약학 제형의 개선된 코 투여
US20210386716A1 (en) Compositions and methods for blocking the cytokine storm of coronavirus and other medical conditions
AU2007201056B2 (en) Treatment of rheumatoid arthritis using imatinib
WO2005053696A1 (en) Treatment of spondylarthropathies
AU2003206783A1 (en) Treatment of rheumatoid arthritis using imatinie